Committee for Medicinal Products for Veterinary Use (CVMP)
The Committee for Medicinal Products for Veterinary Use (CVMP) is the European Medicines Agency's (EMA) committee responsible for veterinary medicines.
- conducting the initial assessment of EU-wide marketing authorisation applications;
- post-authorisation and maintenance activities, including the assessment of any modifications or extensions ('variations') to an existing marketing authorisation;
- safety monitoring of veterinary medicines on the market and when necessary, recommending to the European Commission changes to a medicine's marketing authorisation, or its suspension or withdrawal from the market. For more information, see Veterinary pharmacovigilance.
The CVMP recommends safe limits for residues of veterinary medicines used in food-producing animals and biocidal products used in animal husbandry, for the establishment of maximum residue limits by the European Commission.
- providing scientific advice to companies researching and developing new veterinary medicines;
- preparing scientific guidelines and regulatory guidance to help pharmaceutical companies prepare marketing authorisation applications for veterinary medicines;
- cooperate with international partners on the harmonisation of regulatory requirements.
The CVMP's assessments are based on a comprehensive scientific evaluation of data. They determine whether the medicine meets the necessary quality, safety and efficacy requirements and that is has a positive risk-benefit balance in favour of the animal population they are intended for.
A peer-review system safeguards the accuracy and validity of the opinions of the committee.
For full details, see: